Trial record 1 of 2 for:    b2335
Previous Study | Return to List | Next Study

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00677807
First received: May 13, 2008
Last updated: August 18, 2011
Last verified: August 2011
  Purpose

This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients


Condition Intervention Phase
COPD
Drug: Indacaterol
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo [ Time Frame: Up to 52 weeks ] [ Designated as safety issue: Yes ]

    The number of participants with newly occurring or worsening clinically notable vital sign: Pulse Rate in beats per minute (bpm) at anytime post baseline (BL) by treatment.

    Low Pulse Rate was defined as a pulse rate: <40 bpm or <= to 50 bpm and a decrease from baseline >= to 15 bpm.

    High Pulse Rate was defined as a pulse rate: >130 bpm or >= to 120 bpm and an increase from baseline >= to 15 bpm.


  • The Number of Participants With a Clinically Notable Systolic Blood Pressure During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo [ Time Frame: Up to 52 weeks ] [ Designated as safety issue: Yes ]

    The number of participants with newly occurring or worsening clinically notable vital sign: Systolic Blood Pressure (mmHg) at anytime post baseline (BL) by treatment.

    A Low Systolic Blood Pressure was defined as a systolic blood pressure measurement: <75 mmHg or <= to 90 mmHg and a decrease from baseline >= to 20 mmHg.

    A High Systolic Blood Pressure was defined as a systolic blood pressure measurement: >200 mmHg or >= to 180 mmHg and an increase from baseline >= to 20 mmHg.


  • The Number of Participants With a Clinically Notable Diastolic Blood Pressure During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo [ Time Frame: Up to 52 weeks ] [ Designated as safety issue: Yes ]

    The number of participants with newly occurring or worsening clinically notable vital sign: Diastolic Blood Pressure (mmHg) at anytime post baseline (BL) by treatment.

    A Low Diastolic Blood Pressure was defined as a diastolic blood pressure measurement: <40 mmHg or <= to 50 mmHg and a decrease from baseline >= to 15 mmHg.

    A High Diastolic Blood Pressure was defined as a diastolic blood pressure measurement: >115 mmHg or >= to 105 mmHg and an increase from baseline >= to 15 mmHg.


  • The Number of Participants With a Clinically Notable QTc Interval Value During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo [ Time Frame: Up to 52 weeks ] [ Designated as safety issue: Yes ]

    The number of participants with newly occurring or worsening clinically notable QTc Interval value at anytime post baseline.

    The QTc interval is calculated using Fridericia's formula: QTc= QT/cube root RR. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves in milliseconds (ms).

    Notable QTC interval= >450 ms for males and >470 ms for females. The maximum QTC increase from pre to post dose at any time during the study was also tabulated with absolute and relative frequencies for categories 30- 60 ms and >60 ms.


  • Serum Potassium (mmol/L) 1 Hour Post-dose at Weeks 12, 26, 36, 44 and 52 [ Time Frame: Weeks 12, 26, 36, 44 and 52 ] [ Designated as safety issue: No ]
    The least squares mean of the serum potassium in mmol/L at weeks 12, 26, 36, 44 and 52. Mixed model used baseline serum potassium as a covariate.

  • Blood Glucose (mmol/L) 1 Hour Post Dose at Weeks 12, 26, 36, 44 and 52 [ Time Frame: Weeks 12, 26, 36, 44 and 52 ] [ Designated as safety issue: No ]
    The least squares mean of the blood glucose in mmol/L at weeks 12, 26, 36, 44 and 52. Mixed model used baseline blood glucose as a covariate.


Secondary Outcome Measures:
  • Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 52 of Treatment [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Spirometry was conducted according to internationally accepted standards. The trough FEV1 was defined as the average of the FEV1 measurements taken at 23 hours 10 minutes and 23 hours 45 minutes post dose at week 52. The mixed model used baseline FEV1 as well as FEV1 reversibility components as covariates.

  • Quality of Life Assessment With St George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 36, 44 and 52 [ Time Frame: Weeks 36, 44 and 52 ] [ Designated as safety issue: No ]

    The least squares mean of the SGRQ total score at weeks 36, 44 and 52. Mixed model used for analysis used baseline SGRQ total score as well as FEV1 reversibility components as covariates.

    SGRQ is a health related quality of life questionnaire consisting of 50 items in three domains: symptoms, activity and impacts. The total score is 0 to 100 with a higher score indicating poorer health. A difference from placebo of -4 in the least squares mean SGRQ total score is considered clinically relevant.



Enrollment: 415
Study Start Date: May 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Indacaterol 150 µg

Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).

The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.

Drug: Indacaterol
Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Experimental: Indacaterol 300 µg

Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).

The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.

Drug: Indacaterol
Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Placebo Comparator: Placebo

Placebo once-daily (o.d.) via SDDPI.

The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.

Drug: Placebo
Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients eligible to participate in the study extension, by definition, will have met the inclusion and exclusion criteria for the core 26 weeks and not met the withdrawal criteria for the core study B2335S at Visit 14 (the last visit of the core study B2335S and the first visit of the extension study B2335SE).
  • In addition the following inclusion/exclusion criteria specified below must be met.

    1. Patients must complete Stage 2 of the core study B2335S (NCT00463567).
    2. Written informed consent to participate in the extension must be obtained.
    3. Patients must be able to comply with all study requirements.

Exclusion Criteria:

  • Patients who were randomized to open-label tiotropium in Study B2335S.
  • Patients who participated in Stage 1 of the core study (B2335S).
  • Patients discontinued irrespective of the reason from Stage 2 of the core study.
  • Patients who fail to comply with the core protocol requirements and procedures.
  • Concomitant medical conditions that may interfere with interpretation of study results as defined in the core study protocol.
  • Patients who in the Investigator's opinion should not participate in the extension study.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00677807

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Homewood, Alabama, United States, 35209-6870
Novartis Investigative Site
Jasper, Alabama, United States, 35501
United States, Arizona
Novartis Investigative Site
Phoenix, Arizona, United States, 85013
Novartis Investigative Site
Tucson, Arizona, United States, 85712
United States, Arkansas
Novartis Investigative Site
Pine Bluff, Arkansas, United States, 71603
United States, California
Novartis Investigative Site
Encinitas, California, United States, 92024-1332
Novartis Investigative SIte
Fullerton, California, United States, 92835
Novartis Investigative Site
Orange, California, United States, 92869
Novartis Investigative Site
Riverside, California, United States, 92506
Novartis Investigative Site
Spring Valley, California, United States, 91978
United States, Colorado
Novartis Investigative site
Fort Collins, Colorado, United States, 80528
Novartis Investigative site
Golden, Colorado, United States, 80401
Novartis Investigative Site
Wheat Ridge, Colorado, United States, 80033
United States, Florida
Novartis Investigative Site
Clearwater, Florida, United States, 33765
Novartis Investigative Site
Largo, Florida, United States, 33770
Novartis Investigative Site
Pensacola, Florida, United States, 32504
Novartis Investigative Site
Rockledge, Florida, United States, 32955
Novartis Investigative Site
South Miami, Florida, United States, 33143
Novartis Investigative Site
Tamarac, Florida, United States, 33321
Novartis Investigative Site
Tampa, Florida, United States, 33603
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30342
Novartis Investigative Site
Marietta, Georgia, United States, 30060
United States, Illinois
Novartis Investigative Site
Normal, Illinois, United States, 61761
Novartis Investigative Site
O'Fallon, Illinois, United States, 62269
Novartis Investigative Site
River Forest, Illinois, United States, 60305
United States, Indiana
Novartis Investigative Site
Indianapolis, Indiana, United States, 46256
United States, Iowa
Novartis Investigative Site
Iowa City, Iowa, United States, 52240
Novartis Investigative Site
Iowa City, Iowa, United States, 52242
United States, Kansas
Novartis Investigative Site
Topeka, Kansas, United States, 66606
United States, Kentucky
Novartis Investigative Site
Crescent Springs, Kentucky, United States, 41017
Novartis Investigative Site
Lexington, Kentucky, United States, 40504
Novartis Investigative Site
Lexington, Kentucky, United States, 40536
United States, Louisiana
Novartis Investigative Site
Lafayette, Louisiana, United States, 70503
Novartis Investigative Site
Metaire, Louisiana, United States, 70002
Novartis Investigative site
New Orleans, Louisiana, United States, 70112
United States, Maine
Novartis Investigative Site
Biddeford, Maine, United States, 04005
United States, Michigan
Novartis Investgative Site
Clarkston, Michigan, United States, 48346
Novartis Investigative Site
Flint, Michigan, United States, 48532
Novartis Investigative Site
Livonia, Michigan, United States, 48152
Novartis Investigative site
Troy, Michigan, United States, 48085
United States, Minnesota
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55402
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55407
Novartis Investigative Site
Rochester, Minnesota, United States, 55905
United States, Missouri
Novartis Investigative Site
Chesterfield, Missouri, United States, 63017
Novartis Investigative Site
Columbia, Missouri, United States, 65212
Novartis Investigative Site
Kansas City, Missouri, United States, 64108-2677
Novartis Investigative Site
St Louis, Missouri, United States, 63141
United States, Montana
Novartis Investigative Site
Billings, Montana, United States, 59102
Novartis Investigative Site
Kalispell, Montana, United States, 59901
United States, Nebraska
Novartis Investigative Site
Lincoln, Nebraska, United States, 68510
Novartis Investigative Site
Omaha, Nebraska, United States, 68134
Novartis Investigative Site
Omaha, Nebraska, United States, 68130
Novartis Investigative Site
Omaha, Nebraska, United States, 68198-5885
Novartis Investigative Site
Papillion, Nebraska, United States, 68046
United States, Nevada
Novartis Investigative site
Henderson, Nevada, United States, 89014
United States, New Jersey
Novartis Investigative site
Summit, New Jersey, United States, 07901
United States, New York
Novartis Investigative Site
Elmira, New York, United States, 14905
Novartis Investigative site
New York, New York, United States, 10016
Novartis Investigative Site
Rochester, New York, United States, 14618-2638
United States, North Carolina
Novartis Investigative Site
Charlotte, North Carolina, United States, 28207
Novartis Investigative Site
Shelby, North Carolina, United States, 28150
Novartis Investigative Site
Winston Salem, North Carolina, United States, 27103
United States, North Dakota
Novartis Investigative Site
Fargo, North Dakota, United States, 58122
United States, Ohio
Novartis Investigative Site
Cincinnati, Ohio, United States, 45245
Novartis Investigative Site
Cleveland, Ohio, United States, 44109-1998
Novartis Investigative Site
Columbus, Ohio, United States, 43213
Novartis Investigative Site
Columbus, Ohio, United States, 43215
Novartis Investigative Site
Marion, Ohio, United States, 43302
Novartis Investigative Site
Sylvania, Ohio, United States, 43650
Novartis Investigative Site
Thornville, Ohio, United States, 43076
Novartis Investigative Site
Zanesville, Ohio, United States, 43701
United States, Oklahoma
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73104
Novartis Investigative Site
Tulsa, Oklahoma, United States, 74135-2920
United States, Oregon
Novartis Investigative Site
Eugene, Oregon, United States, 97404-3233
Novartis Investigative Site
Medford, Oregon, United States, 97504-8741
United States, Pennsylvania
Novartis Investigative Site
Erie, Pennsylvania, United States, 16506
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15221
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15243
United States, Rhode Island
Novartis Investigative site
Cranston, Rhode Island, United States, 02920
Novartis Investigative Site
Cumberland, Rhode Island, United States, 02864
United States, South Carolina
Novartis Investigative Site
Greenville, South Carolina, United States, 29615
United States, Tennessee
Novartis Investigative Site
Johnson City, Tennessee, United States, 37601
United States, Texas
Novartis Investigative Site
Corsicana, Texas, United States, 75110
Novartis Investigative Site
Dallas, Texas, United States, 75231
Novartis Investigative site
El Paso, Texas, United States, 79902
Novartis Investigative Site
Fort Worth, Texas, United States, 76104
Novartis Investigative Site
San Antonio, Texas, United States, 78229
United States, Virginia
Novartis Investigative Site
Abingdon, Virginia, United States, 24210
Novartis Investigative site
Lynchburg, Virginia, United States, 24501
Novartis Investigative Site
Richmond, Virginia, United States, 23249
United States, Washington
Novartis Investigative Site
Bellingham, Washington, United States, 98225
Novartis Investigative site
Spokane, Washington, United States, 99216
United States, Wisconsin
Novartis Investigative Site
Milwaukee, Wisconsin, United States, 53209-0996
Argentina
Novartis Investigative site
Buenos Aires, Argentina
Novartis Investigative site
Rosario, Argentina
Canada
Novartis Investigative site
Ajax, Canada
Novartis Investigative site
Calgary, Canada
Novartis Investigative site
Gatineau, Canada
Novartis Investigative site
Moncton, Canada
Novartis Investigative site
Montreal, Canada
Novartis Investigative site
Niagara Falls, Canada
Novartis Investigative site
Ottawa, Canada
Novartis Investigative site
Quebec, Canada
Novartis Investigative site
Saskatoon, Canada
Novartis Investigative site
Sherbrooke, Canada
Novartis Investigative site
St-Romuald, Canada
Novartis Investigative site
St. John, Canada
Novartis Investigative site
St. John's, Canada
Novartis Investigative site
Toronto, Canada
Novartis Investigative site
Trois-Rivières, Canada
Novartis Investigative site
Vancouver, Canada
Novartis Investigative site
Windsor, Canada
Novartis Investigative site
Winnipeg, Canada
Germany
Novartis Investigative site
Augsburg, Germany
Novartis Investigative site
Bad Segeberg, Germany
Novartis Investigative site
Berlin, Germany
Novartis Investigative site
Bielefeld, Germany
Novartis Investigative site
Bonn, Germany
Novartis Investigative site
Dachau, Germany
Novartis Investigative site
Hamburg, Germany
Novartis Investigative site
Hoyerswerda, Germany
Novartis Investigative site
Kaufbeuren, Germany
Novartis Investigative site
Landsberg, Germany
Novartis Investigative site
Leipzig, Germany
Novartis Investigative site
Mainz, Germany
Novartis Investigative site
Muenchen, Germany
Novartis Investigative site
Oranienburg, Germany
Novartis Investigative site
Oschersleben, Germany
Novartis Investigative site
Potsdam, Germany
Novartis Investigative site
Ratingen, Germany
Novartis Investigative site
Steinfurt-Borghorst, Germany
India
Novartis Investigator Site
Bangalore, India
Novartis Investigative Site
Chennai, India
Novartis Investigative Site
Coimbatore, India
Novartis Investigator Site
Coimbatore, India
Novartis Investigator Site
Hyderabaad, India
Novartis Investigator Site
Indore, India
Novartis Investigator Site
Jaipur, India
Novartis Investigator Site
Kolkata, India
Novartis Investigator Site
Ludhiana, India
Novartis Investigative Site
Mumbai, India
Novartis Investigator Site
Panjim, India
Novartis Investigator Site
Trivandrum, India
Italy
Novartis Investigator Site
Bologna, Italy
Novartis Investigator Site
Busto Arsizio, Italy
Novartis Investigator Site
Catania, Italy
Novartis Investigator Site
Catanzaro, Italy
Novartis Investigator Site
Crema, Italy
Novartis Investigator Site
Ferrara, Italy
Novartis Investigator Site
Firenze, Italy
Novartis Investigator Site
Messina, Italy
Novartis Investigator Site
Milano, Italy
Novartis Investigator Site
Pisa, Italy
Novartis Investigator Site
Roma, Italy
Novartis Investigator Site
Rozzano, Italy
Novartis Investigator Site
Siena, Italy
Novartis Investigator Site
Sottomarina, Italy
Spain
Novartis Investigator Site
Alicante, Spain
Novartis Investigator Site
Alzira, Spain
Novartis Investigator Site
Barcelona, Spain
Novartis Investigator Site
Burgos, Spain
Novartis Investigator Site
Cordoba, Spain
Novartis Investigator Site
Girona, Spain
Novartis Investigator Site
Gladakano, Spain
Novartis Investigator Site
Jerez de Frontera, Spain
Novartis Investigator Site
La Coruna, Spain
Novartis Investigator Site
Las Palmas de Gran Canaria, Spain
Novartis Investigator Site
Las Palmas de Gran Canarias, Spain
Novartis Investigator Site
Lugo, Spain
Novartis Investigator Site
Madrid, Spain
Novartis Investigator Site
Malaga, Spain
Novartis Investigator Site
Orense, Spain
Novartis Investigator Site
Oviedo, Spain
Novartis Investigator Site
Palma De Mallorca, Spain
Novartis Investigator Site
Ponferrada, Spain
Novartis Investigative Site
Pontevedra, Spain
Novartis Investigator Site
Puerto de Sagunto, Spain
Novartis Investigative Site
Sevilla, Spain
Novartis Investigator Site
Valencia, Spain
Novartis Investigator Site
Vic, Spain
Novartis Investigator Site
Vila-real, Spain
Novartis Investigative Site
Zaragoza, Spain
Sweden
Novartis Investigative Site
Goteborg, Sweden
Novartis Investigator Site
Jonkoping, Sweden
Novartis Investigative Site
Lidingo, Sweden
Novartis Investigator Site
Lulea, Sweden
Novartis Investigative Site
Lulea, Sweden
Novartis Investigator Site
Lund, Sweden
Turkey
Novartis Investigative Site
Kartal/Istanbul, Turkey
Novartis Investigator Site
Mersin, Turkey
Novartis Investigator Site
Yenisehir/Izmir, Turkey
Sponsors and Collaborators
Novartis
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: External Affairs, Novartis
ClinicalTrials.gov Identifier: NCT00677807     History of Changes
Other Study ID Numbers: CQAB149B2335SE, 2008-000663-42
Study First Received: May 13, 2008
Results First Received: July 22, 2011
Last Updated: August 18, 2011
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Canada: Health Canada
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
India: Institutional Review Board
Italy: The Italian Medicines Agency
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
Turkey: Ministry of Health

Keywords provided by Novartis:
COPD
adults
β2-agonist
indacaterol

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014